Abstract | AIM: MATERIALS AND METHODS: A total of 46 patients were randomly assigned to either group 1 (control group) or group 2 (CIK group) using blocked randomization. Both groups received the FOLFOX4 (5-fluorouridine, leucovorin, and oxaliplatin) CT. In the CIK group, patients were given CIK cell infusion after FOLFOX4 CT. Treatment efficacy, adverse effects, and quality of life (QOL) were assessed. RESULTS: During the first 2 years of follow-up, the recurrence rate in the CIK group (26.1%, 6 in 23 cases) was significantly lower than the control group (43.5%, 10 in 23). The survival time was significantly longer in the CIK group (41.9 months, 95% confidence interval [CI]: 38.2-45.7) than in the control group (33.8 months, 95% CI: 28.4-39.2). Although QOL was reduced in both treatment groups, adjuvant CIK cell transfusion significantly improved the QOL in patients with CRC. Toxicity was mild in patients with CIK treatment. CONCLUSIONS:
Immunotherapy with CIK cells may serve as an adjuvant treatment in patients with CRC after CT with prolonged survival of patients, limited side-effects, and improved QOL.
|
Authors | Hao Peng, Meng Yao, Hongwei Fan, Liwei Song, Jinwen Sun, Zheng Zhou, Yunfeng Du, Keyu Lu, Tao Li, Aiguo Yin, Jianhua Xu, Shidong Wei |
Journal | Cancer biotherapy & radiopharmaceuticals
(Cancer Biother Radiopharm)
Vol. 32
Issue 6
Pg. 221-226
(Aug 2017)
ISSN: 1557-8852 [Electronic] United States |
PMID | 28820635
(Publication Type: Journal Article)
|
Topics |
- Colorectal Neoplasms
(genetics, mortality, therapy)
- Cytokine-Induced Killer Cells
(metabolism)
- Female
- Humans
- Immunotherapy
(methods)
- Middle Aged
- Prospective Studies
- Quality of Life
- Survival Analysis
|